Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

    Not Recruiting
  • participants needed
  • sponsor
    Q-Med AB
Updated on 4 August 2021
Sr. Clinical Project Manager
Primary Contact
ArteMedica (2.2 mi away) Contact
+29 other location


This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Condition Glabellar Lines, Lateral Canthal Lines
Treatment botulinum toxin neuromodulator
Clinical Study IdentifierNCT04225260
SponsorQ-Med AB
Last Modified on4 August 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note